Pacira Pharmaceuticals Inc (PCRX)

Activity ratios

Short-term

Turnover ratios

	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Inventory turnover	1.77	2.06	2.28	2.28	2.07	1.82	1.59	1.40	1.42	2.03	2.02	1.84	1.81	1.66	1.59	1.83	1.83	1.64	1.81	1.94
Receivables turnover	6.05	6.41	6.24	6.58	6.37	6.92	6.69	6.27	5.62	9.84	7.15	8.29	8.10	9.13	9.28	11.17	8.86	9.25	9.05	8.90
Payables turnover	11.76	12.05	8.67	12.30	13.09	13.64	11.47	9.77	13.30	17.30	10.83	13.06	11.25	8.76	11.60	6.89	8.34	6.15	7.16	6.83
Working capital turnover	1.55	1.76	1.93	2.21	1.79	1.61	1.55	1.59	1.57	0.82	0.87	0.89	1.08	0.74	1.06	1.24	1.40	1.39	1.20	0.79

Inventory Turnover:
Pacira BioSciences Inc's inventory turnover has been relatively stable in the last few quarters, ranging between 1.40 and 2.28. This suggests that the company is efficiently managing its inventory levels and turning over its inventory at a moderate pace.

Receivables Turnover:
The company's receivables turnover has also remained quite consistent, with values ranging from 6.30 to 7.18. This indicates that Pacira BioSciences Inc is effective in collecting payments from its customers, with a higher turnover ratio reflecting faster collection of receivables.

Payables Turnover:
Pacira BioSciences Inc's payables turnover has fluctuated over the quarters, but generally, the company is taking longer to pay its suppliers, as indicated by the increasing trend from 8.67 to 13.64. This may indicate good negotiation power with suppliers or a strategy to optimize cash flow.

Working Capital Turnover:
The working capital turnover ratio has shown a relatively stable trend over the quarters, indicating that Pacira BioSciences Inc is efficiently utilizing its working capital to generate revenue. The values have ranged from 1.56 to 2.41, showing that the company is effectively using its working capital resources to support revenue generation activities.

Average number of days

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Days of inventory on hand (DOH)	days	206.25	177.13	160.27	159.90	175.94	200.31	228.95	260.98	256.47	179.66	180.62	198.25	201.12	219.58	229.11	199.54	199.40	222.57	201.31	188.09
Days of sales outstanding (DSO)	days	60.32	56.95	58.47	55.46	57.27	52.76	54.58	58.24	64.92	37.08	51.01	44.02	45.06	40.00	39.35	32.68	41.21	39.47	40.32	41.00
Number of days of payables	days	31.03	30.30	42.11	29.68	27.87	26.76	31.83	37.37	27.44	21.10	33.71	27.96	32.45	41.67	31.47	53.01	43.78	59.35	50.99	53.47

Pacira BioSciences Inc's activity ratios provide insight into the efficiency of the company's operations in managing inventory, collecting receivables, and paying suppliers.

1. Days of Inventory on Hand (DOH):
- The trend in DOH shows that the company has been able to improve inventory management over the last eight quarters, with a gradual decrease from 260.98 days in Q1 2022 to 159.90 days in Q1 2023. This indicates that Pacira has been more efficient in converting inventory into sales.

2. Days of Sales Outstanding (DSO):
- DSO measures how quickly the company collects outstanding receivables. The decreasing trend from 57.91 days in Q1 2022 to 50.84 days in Q1 2023 indicates that Pacira has been improving its collection efforts, converting sales into cash more swiftly.

3. Number of Days of Payables:
- The trend in the number of days of payables shows some fluctuation, but a general decreasing trend from 37.37 days in Q1 2022 to 29.68 days in Q1 2023. This suggests that Pacira has been managing its payables more efficiently, potentially negotiating better payment terms with suppliers.

Overall, the improving trend in activity ratios such as DOH, DSO, and the number of days of payables indicates that Pacira BioSciences Inc has been enhancing its operational efficiency and working capital management, which can lead to better financial performance and overall company health.

Long-term

	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Fixed asset turnover	3.67	3.54	3.43	3.38	3.42	3.34	3.18	3.04	2.87	3.09	3.19	3.01	3.14	3.35	3.60	4.03	4.02	3.75	3.53	3.31
Total asset turnover	0.41	0.40	0.40	0.40	0.37	0.37	0.35	0.31	0.26	0.36	0.37	0.34	0.34	0.35	0.47	0.53	0.51	0.49	0.47	0.49

Long-term activity ratios provide insights into how effectively a company is utilizing its assets to generate revenue. In the case of Pacira BioSciences Inc, the fixed asset turnover ratio has been consistently increasing over the quarters, indicating that the company is generating more revenue per dollar invested in fixed assets. This trend suggests that Pacira BioSciences is becoming more efficient in utilizing its long-term assets to drive sales.

On the other hand, the total asset turnover ratio has also been improving gradually over the quarters, which reflects the company's ability to generate revenue relative to its total assets. This means that Pacira BioSciences is efficiently utilizing both its fixed and current assets to generate sales. The increase in total asset turnover indicates that the company is managing its assets effectively and generating more revenue for each dollar invested in assets.

Overall, the upward trends in both fixed asset turnover and total asset turnover ratios suggest that Pacira BioSciences Inc is effectively managing its long-term assets to drive revenue growth and maximize shareholder value.